Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Antibody antagonists of the insulinotropic receptor GIPR prevent weight gain in obese animal models, and the effect is enhanced by GLP-1R agonists.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Combined, the SURPASS and SURMOUNT trials have verified the safety of tirzepatide to be consistent with GLP-1R agonists, along with its enhanced efficacy at maximal doses of 5, 10 and 15 mg (Table 1)132-136,143,145-147”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [146]
In the citing paper
“agonists and antagonists of the GIP receptor (GIPR) are currently in development, both of which have paradoxically demonstrated the ability to potentiate the weight reduction of GLP-1R agonists in preclinical models [[32], [33], [34], [35], [36], [37]]”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [33]
In the citing paper
“Neutralizing GIPR antibodies, which are presumably sequestered to the periphery, reduce body weight in an independent manner to food intake and modify energetic substrate utilization in vivo [33]”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [33]
In the citing paper
“The combination of an anti-GIPR monoclonal antibody (mAb) and a GLP-1RA has been shown to mediate more pronounced weight loss than either agent alone in preclinical obesity models33.”
From A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings (2024) · cites this paper as [33]
In the citing paper
“However, it has been shown in animal models that GIP RAs potentiates GLP-1-induced weight loss and reduces food intake [164,165].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [165]
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
How good are my data and what is the resolution?
Evans, P. R., & Murshudov, G. N. (2013) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444913000061 · Cited by 4,697
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Postic, C., Shiota, M., Niswender, K. D., Jetton, T. L., Chen, Y., Moates, J. M., Shelton, K. D., Lindner, J., Cherrington, A. D., & Magnuson, M. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.1.305 · Cited by 1,302
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 4×
“This finding has not been observed in GIPR KO mouse models (9, 22, 32) or in other therapies targeting the GIP/GIPR axis (31).”
BackgroundMethodResultInfluential
Cited by
Items 101–200 of 238
An integrative framework to prioritize genes in more than 500 loci associated with body mass index
Hemerich, D., Svenstrup, V., Díez‐Obrero, V., Preuss, M. H., Moscati, A., Hirschhorn, J. N., & Loos, R. J. F. (2024) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2024.04.016 · Cited by 29
Guccio, N., Gribble, F. M., & Reimann, F. (2022) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-062320-113625 · Cited by 36
The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue
Kagdi, S., Lyons, S. A., & Beaudry, J. L. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0361 · Cited by 33
Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway
Ni, X., Feng, X., Wang, Z., Zhang, Y., Little, P. J., Cao, Y., Xu, S., Tang, L., & Weng, J. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01265-0 · Cited by 29
Self-citationGóralska, J., Raźny, U., Polus, A., Dziewońska, A., Gruca, A., Zdzienicka, A., Dembinska-Kiec, A., Solnica, B., Micek, A., Kapusta, M., et al. (2020) · Nutrients · doi:10.3390/nu12020476 · Cited by 26
Muzurović, E. M., Katsiki, N., Volčanšek, Š., Plescia, F., Rizzo, M., & Mantzoros, C. S. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156494 · Cited by 25
Bulum, T. (2022) · Biomedicines · doi:10.3390/biomedicines10102586 · Cited by 31
“Contrary to GIP monotherapy, when administered with GLP-1 receptor agonists, its combination strongly decreases body weight [57].”
BackgroundThe antiemetic actions of GIP receptor agonism
Borner, T., Jonghe, B. C. D., & Hayes, M. R. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00330.2023 · Cited by 28
GIP-derived GIP receptor antagonists – a review of their role in GIP receptor pharmacology
ROSENKILDE, M. M., Lindquist, P., Kizilkaya, H. S., & Gasbjerg, L. S. (2024) · Peptides · doi:10.1016/j.peptides.2024.171212 · Cited by 22
“GIP also stimulates glucagon secretion when blood glucose is low (fasting state) [20,87,88]. r Therapeutically targeting the GIPR will presumably result in similar effects. u Long-term GIPR stimulation or blockade might, however, be expected to promote adaptations at both receptor signalling,…”
Dual gut hormone receptor agonists for diabetes and obesity
Bass, J., Tschöp, M. H., & Beutler, L. R. (2023) · Journal of Clinical Investigation · doi:10.1172/jci167952 · Cited by 21
Chrysavgis, L., Kazanas, S., Bafa, K., Rozani, S., Koloutsou, M. E., & Cholongitas, Ε. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073832 · Cited by 27
“The administration of a mouse anti-murine anti-GIPR antibody in both mice and obese nonhuman primates was associated with reduced food intake, resting respiratory exchange ratio, and body weight gain [134].”
BackgroundResultHan, W., Wang, L., Ohbayashi, K., Takeuchi, M., O’Farrell, L. S., Coşkun, T., Rakhat, Y., Yabe, D., Iwasaki, Y., Seino, Y., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15001 · Cited by 22
Why are we still in need for novel anti-obesity medications?
Novikoff, A., Grandl, G., Liu, X., & Müller, T. D. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.101098 · Cited by 22
Perry, R., Craig, S., Ng, M., Gault, V. A., Flatt, P. R., & Irwin, N. (2019) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/1179551419875453 · Cited by 20
“hGIP(3-30), mGIP(3-30) and h(Pro3)GIP(3-30) were able to significantly (P < 0.”
BackgroundInfluentialLiu, C., Li, C., Cai, X., Zou, Y., Mo, J., chen, B., Cai, Y., Han, T., Huang, W., Qian, H., et al. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104492 · Cited by 20
Therapeutic Targeting of the GIP Receptor—Revisiting the Controversies
Campbell, J. E., & Drucker, D. J. (2025) · Diabetes · doi:10.2337/db25-0393 · Cited by 22
Revisiting the concept of incretin and enteroendocrine L-cells as type 2 diabetes mellitus treatment
Lok, K.-H., Wareham, N. J., Nair, R. S., How, C. W., & Chuah, L. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106237 · Cited by 19
Park, S., Oh, S., & Kim, E. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102682 · Cited by 20
“This might be due to the fact that liraglutide does not completely revert the obese phenotype to a nonobese state, but makes the phenotype milder (19, 60, 61).”
BackgroundDiscovery and design of G protein-coupled receptor targeting antibodies
Peterson, S. M., Hutchings, C. J., Hu, C. F., Mathur, M., Salameh, J. W., Axelrod, F. T., & Sato, A. K. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2193389 · Cited by 20
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
Sidrak, W. R., Kalra, S., & Kalhan, A. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_442_23 · Cited by 27
Chronic GIPR agonism results in pancreatic islet GIPR functional desensitisation
Davies, I., Adriaenssens, A. E., Scott, W. R., Carling, D., Murphy, K. G., MINNION, J. S., Bloom, S. R., Jones, B. J., & Tan, T. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102094 · Cited by 20
Designing poly-agonists for treatment of metabolic diseases: challenges and opportunities
Petersen, J., Strømgaard, K., Frølund, B., & Clemmensen, C. (2019) · Drugs · doi:10.1007/s40265-019-01153-6 · Cited by 17
Regulation of energy metabolism through central GIPR signaling
Liśkiewicz, A., & Müller, T. D. (2024) · Peptides · doi:10.1016/j.peptides.2024.171198 · Cited by 18
“Further consistent with these findings is the observation that certain GIPR antagonists decrease body weight and food intake in diet-induced obese (DIO) mice and non-human primates [48], particularly when given in adjunct to GLP-1R agonism [48, 49].”
Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges
Huang, X., Liu, J., Peng, G., Lu, M., Zhou, Z., Jiang, N., & Yan, Z. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0404 · Cited by 20
The role of GIPR in food intake control
James-Okoro, P.-P., Lewis, J. E., Gribble, F. M., & Reimann, F. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1532076 · Cited by 23
“Emerging evidence suggests that the combination of antibody-based GIPR antagonism and GLP1R agonism leads to more signi fi cant weight loss in mice compared to the weight loss achieved through GLP1R agonism alone (7, 110).”
InfluentialWest, J. A., Ghosh, S. S., Parkes, D. G., Tsakmaki, A., Grønlund, R. V., Pedersen, P. J., MAGGS, D. G., Rajagopalan, H., & Bewick, G. A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249239 · Cited by 19
“There is a compelling body of evidence suggesting that antagonism of this system can produce beneficial effects on adiposity and insulin sensitivity [38, 40, 45, 46].”
BackgroundResultInfluentialFerrulli, A., Terruzzi, I., Senesi, P., Succi, M., Cannavaro, D., & Luzi, L. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.02.016 · Cited by 17
Malik, I. O., Petersen, M. C., & Klein, S. (2022) · Obesity · doi:10.1002/oby.23521 · Cited by 18
“weight loss in mice and nonhuman primates [9], and tirzepatide does not cause weight loss in obese Glp1r / mice [10].”
BackgroundGlucose-Dependent Insulinotropic Polypeptide Is a Pancreatic Polypeptide Secretagogue in Humans
Veedfald, S., Vedtofte, L., Skov‐Jeppesen, K., Deacon, C. F., Hartmann, B., Vilsbøll, T., Knop, F. K., Christensen, M., & Holst, J. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz097 · Cited by 17
RBM5-AS1 promotes radioresistance in medulloblastoma through stabilization of SIRT6 protein
Zhu, C., Li, K., Jiang, M., & Chen, S. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01218-2 · Cited by 18
ROSENKILDE, M. M., George, J. T., Véniant, M. M., & Holst, J. J. (2025) · Diabetes · doi:10.2337/dbi24-0027 · Cited by 19
Self-citationBorner, T., Pataro, A. M., Doebley, S. A., Furst, C. D., White, A. D., Gao, S. X., Chow, A., Sanchez-Navarro, M. J., Ghidewon, M. Y., Halas, J. G., et al. (2025) · Science Advances · doi:10.1126/sciadv.adu1589 · Cited by 21
“Despite this, renewed interest in GIP-based pharmacology has emerged via enhanced metabolic efficacy in several preclinical studies and clinical trials assessing combined co-agonism of the GIPR and GLP-1R ( 11 – 15 ).”
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
Allard, C., Cota, D., & Quarta, C. (2023) · Drugs · doi:10.1007/s40265-023-01982-6 · Cited by 17
“High-fat diet (HFD)-fed mice and non-human primates treated with GIPR antagonists, alone or in combination with GLP1RAs, showed resistance to weight gain and improvement in the glycaemic profile [173–176].”
Douros, J. D., Flak, J. N., & Knerr, P. J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1530985 · Cited by 18
GIPR Agonism Enhances TZD-Induced Insulin Sensitivity in Obese IR Mice
Furber, E. C., Hyatt, K., Collins, K. A. L., Yu, X., Droz, B. A., Holland, A. K., Friedrich, J. L., Wojnicki, S., Konkol, D. L., O’Farrell, L. S., et al. (2023) · Diabetes · doi:10.2337/db23-0172 · Cited by 17
“The LAGIPRA (17) and mouse selective GIPR antagonist antibody (29) were synthesized by Eli Lilly and Company.”
MethodResultFu, Y., Ge, Y., Yi, S., Peng, Q., Jiang, H., & Zhou, J. (2025) · Discover Oncology · doi:10.1007/s12672-025-03079-w · Cited by 19
An oral GLP-1 and GIP dual receptor agonist improves metabolic disorders in high fat-fed mice
Ma, T., Lu, W., Wang, Y., Qian, P., Tian, H., Gao, X., & Yao, W. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174635 · Cited by 14
Quiñones, M., Fernø, J., Diéguez, C., Nogueiras, R., & Al–Massadi, O. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1583642 · Cited by 14
G protein-coupled receptors and obesity
Pocai, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1301017 · Cited by 16
“…reports of pharmacological and genetic deletion of GIPR, Killion et al. showed that an antagonist mAb to the GIPR resulted in food intake and body weight reduction in obese non-human primates and that the combination of GLP-1 agonist and GIPR antagonism resulted in additive weight loss (68, 77).”
BackgroundEriksson, O., Velikyan, I., Haack, T., Bossart, M., Evers, A., Lorenz, K., Laitinen, I., Larsen, P. J., Plettenburg, O., Johansson, L., et al. (2021) · Diabetes · doi:10.2337/db20-1096 · Cited by 13
Douros, J. D., Mowery, S. A., & Knerr, P. J. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113812 · Cited by 12
“The second explanation is that chronic GIPR agonism induces functional antagonism [33,63].”
Incretin receptor agonism rapidly inhibits AgRP neurons to suppress food intake in mice
McMorrow, H. E., Cohen, A. B., Lorch, C. M., Hayes, N. W., Fleps, S. W., Frydman, J. A., Xia, J. L., Samms, R. J., & Beutler, L. R. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186652 · Cited by 12
Bhushan, B., Granata, D., Kaas, C. S., Kasimova, M. A., Ren, Q., Cramer, C. N., White, M. D., Hansen, A. M. K., Fledelius, C., Invernizzi, G., et al. (2022) · Chemical Science · doi:10.1039/d1sc06844j · Cited by 16
Pharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don’t
Novikoff, A., & Müller, T. D. (2024) · Physiology · doi:10.1152/physiol.00032.2023 · Cited by 15
Boer, G. A., Hunt, J. E., Gabe, M. B. N., Windeløv, J. A., Sparre‐Ulrich, A. H., Hartmann, B., Holst, J. J., & ROSENKILDE, M. M. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15894 · Cited by 13
“These results are similar to those observed in mice treated with a GIP receptor antibody, which also exhibited lower fasting glucose levels but no change in glucose curves during an oral glucose tolerance test (Killion et al., 2018).”
BackgroundResultInfluentialThe evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 21
“Instead, co-treatment with GLP1R agonists results in synergistic metabolic improvements in both mice and non-human primates 91,92,95 .”
Antagonizing GIPR adds fire to the GLP-1R flame
Novikoff, A., & Müller, T. D. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.04.016 · Cited by 12
“This antagonistic approach has presented therapeutic opportunity to limit fat mass gain without clearly affecting food intake, and thus partly underlies conceptual development behind the fi rst GLP-1/hGIPRab [10].”
InfluentialYammine, L., Picatoste, B., Abdullah, N., Leahey, R. A., Johnson, E. F., Gómez-Banoy, N., Rosselot, C., Wen, J., Hossain, T., Goncalves, M. D., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101831 · Cited by 10
“Studies have targeted either GIP [73,84] or GIPR [85] with antagonist antibodies and have revealed a protective effect against diet-induced body weight gain.”
BackgroundNovel approaches to anti-obesity drug discovery with gut hormones over the past 10 years
Rose, F., Bloom, S. R., & Tan, T. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1646243 · Cited by 11
“Paradoxically, a GIPR antibody which blocks GIP signalling has also been reported to lower body weight in obese mice and non-human primates [76].”
BackgroundAl‐Zaid, B., Chacko, S., Ezeamuzie, C. I., Bünemann, M., Krasel, C., Karimian, T., Lanzerstorfer, P., & Al‐Sabah, S. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1013 · Cited by 10
Immune-based cancer therapies: mechanistic insights, clinical progress, and future directions
Devaraji, M., & Cheriyan, B. V. (2025) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-025-00319-6 · Cited by 21
Stensen, S., Krogh, L. S. L., Sparre‐Ulrich, A. H., Dela, F., Hartmann, B., Vilsbøll, T., Holst, J. J., ROSENKILDE, M. M., Christensen, M., Gasbjerg, L. S., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14736 · Cited by 11
“Blood samples for analysis of plasma/serum glucose, glucagon, total GIP, total GLP-1, GIP(3-30)NH2, C-peptide, insulin, paracetamol, and lipids, as well as the SAT biopsies, were handled as previously described.”
BackgroundMethodInfluentialThe Location of Missense Variants in the Human GIP Gene Is Indicative for Natural Selection
Lindquist, P., Gasbjerg, L. S., Mokrosiński, J., Holst, J. J., Hauser, A. S., & ROSENKILDE, M. M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.891586 · Cited by 11
“In addition to these well-characterized N- and Cterminally truncated variants, another fragment of the pre-proGIP precursor, GIP_HUMAN[22-51], was recently discovered.”
BackgroundIncretin hormones and pharmacomimetics rapidly inhibit AgRP neuron activity to suppress appetitePreprint
McMorrow, H. E., Lorch, C. M., Hayes, N. W., Fleps, S. W., Frydman, J. A., Xia, J. L., Samms, R. J., & Beutler, L. R. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.18.585583 · Cited by 10
“By contrast, other studies have shown that global GIPR knockout mice are protected from both obesity and insulin resistance when fed a high-fat diet 32-36 , and GIPR antagonism coupled with GLP-1R agonism leads to weight loss in early clinical trials 37,38 and mouse models 25,29 .”
BackgroundMethodResultSmart control lipid-based nanocarriers for fine-tuning gut hormone secretion
Xu, Y., Michalowski, C. B., Koehler, J. A., Darwish, T., Guccio, N., Alcaino, C., Domingues, I., Zhang, W., Marotti, V., Hul, M. V., et al. (2024) · Science Advances · doi:10.1126/sciadv.adq9909 · Cited by 10
“Coadministration of agonists and antagonists of gut peptide receptors has also shown some therapeutic promise, such as the co-administration of a GLP-1 agonist and a GIP antagonist ( 13 , 14 ).”
The evolution of the therapeutic concept ‘GIP receptor antagonism’
Koefoed-Hansen, F., Helsted, M. M., Kizilkaya, H. S., Lund, A., ROSENKILDE, M. M., & Gasbjerg, L. S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1570603 · Cited by 9
Is polypharmacy the future for pharmacological management of obesity?
Lafferty, R. A., Flatt, P. R., & Irwin, N. (2022) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2022.100322 · Cited by 12
Davies, I., & Tan, T. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2203911 · Cited by 10
Differential Responses of the GLP-1 and GLP-2 Receptors to N-Terminal Modification of a Dual Agonist
Gibadullin, R., Cary, B. P., & Gellman, S. H. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c01628 · Cited by 10
What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?
Holst, J. J. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100284 · Cited by 9
“Nevertheless, with the current study, the authors from Amgen Inc. have provided the scientific community with a stimulating input to the current debate regarding the role of GIP, GLP-1, and their combination in metabolic regulation.”
BackgroundInfluentialMin, X., Yie, J., Wang, J., Chung, B. C., Huang, C.-S., Xu, H., Yang, J., Deng, L., Lin, J., Chen, Q., et al. (2020) · mAbs · doi:10.1080/19420862.2019.1710047 · Cited by 10
“In a pharmacokinetic study, a single IP injection of mAb2 demonstrated a prolonged half-life of 12–13 days over a dose range of 1 to 100 mg/kg.(32) Body weights and metabolic profiles (glucose, insulin, triglyceride, and total cholesterol levels) were measured during the treatments.”
BackgroundMethodResultInfluentialSelf-citationThe unexpected role of GIP in transforming obesity treatment
Zandvakili, I., & Pérez–Tilve, D. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.07.022 · Cited by 9
Optimizing treatment of cardiovascular risk factors in cerebral small vessel disease using genetics
Koohi, F., Harshfield, E. L., Gill, D., Ge, W., Burgess, S., & Markus, H. S. (2024) · Brain · doi:10.1093/brain/awae399 · Cited by 14
Pharmacotherapy for chronic obesity management: a look into the future
Abdel-Malek, M., Yang, L., & Miras, A. D. (2023) · Internal and Emergency Medicine · doi:10.1007/s11739-023-03237-4 · Cited by 14
“onstrated effective suppression of body weight rise in obese mice and non-human primates [26, 27].”
BackgroundPeptibodies: Bridging the gap between peptides and antibodies
Khezri, H., Mostafavi, M., Dabirmanesh, B., & Khajeh, K. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134718 · Cited by 10
Gaffey, R. H., Takyi, A. K., & Shukla, A. P. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2377319 · Cited by 8
“As a result, GIP-antagonism via antibodies has been studied successfully as a weight-loss therapy in non-human models coupled to a GLP-1 receptor agonist with success [54].”
Seno, Y., Ikeguchi, E., & Yabe, D. (2025) · Diabetology International · doi:10.1007/s13340-025-00818-w · Cited by 10
“A GIP receptor-neutralizing antibody has demonstrated efficacy in suppressing diet-induced obesity in both murine models and non-human primates [91].”
Tsakiridis, E. E., & Steinberg, G. R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70624 · Cited by 10
Lafferty, R. A., Flatt, P. R., Gault, V. A., & Irwin, N. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0339 · Cited by 8
Alcaino, C., Reimann, F., & Gribble, F. M. (2024) · The Journal of Physiology · doi:10.1113/jp286293 · Cited by 10
“In diet-induced obese mice and obese non-human primates GIPR antagonism acutely reduced food intake (Killion et al., 2018), leading to the question of how both GIPR agonism and GIPR antagonism can reduce feeding.”
Emanuelsson, F., Nordestgaard, B. G., & Benn, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf779 · Cited by 6
Alavi, S. E., Boshrouyeh, R., Raza, A., & Shahmabadi, H. E. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118587 · Cited by 6
Duodenal enteroendocrine cells and GIP as treatment targets for obesity and type 2 diabetes
Bailey, C. J., & Flatt, P. R. (2024) · Peptides · doi:10.1016/j.peptides.2024.171168 · Cited by 6
Gojani, E. G., Wang, B., Li, D., Kovalchuk, O., & Kovalchuk, I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26010421 · Cited by 9
GIPR gene expression in testis is mouse specific and can impact male mouse fertility
Killion, E. A., Hussien, R., Shkumatov, A. A., Davies, R., Lloyd, D. J., Véniant, M. M., Lebrec, H. N., & Fort, M. M. (2022) · Andrology · doi:10.1111/andr.13166 · Cited by 7
Self-citationAntiobesogenic effects of central GIPR antagonism
Yue, J. T. Y., & Lam, T. K. T. (2019) · Journal of Clinical Investigation · doi:10.1172/jci130755 · Cited by 7
The GIPR is Predominantly Localized to Non-Adipocyte Cell Types Within White Adipose Tissue
Campbell, J. E., Beaudry, J. L., Svendsen, B., Baggio, L. L., Gordon, A. N., Ussher, J. R., Wong, C. K., Gribble, F. M., D’Alessio, D. A., Reimann, F., et al. (2022) · doi:10.2337/figshare.19184462 · Cited by 6
GLP-1 and GIP: Magic bullet for musculoskeletal diseases?
Fang, Q., Gan, L., Liu, P., Ding, P., & Gao, Y. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.08.046 · Cited by 6
“The use of this antagonist alone or with GLP-1RA also resulted in significant weight loss in nonhuman primates and mice [179].”
Targeting the Enteroendocrine System for Treatment of Obesity
Miedzybrodzka, E. L., Gribble, F. M., & Reimann, F. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2022_583 · Cited by 5
Diabetic Foot - Recent Advances
Raghav, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.102211 · Cited by 5
Sun, T., Yu, H., Zhang, D., Zhang, D., Li, D., & Fu, J. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103586 · Cited by 8
“The function of GLP-1R signaling has mainly been studied in metabolic diseases such as diabetes mellitus and obesity [26,27].”
Obesity-driven hunger: From pathophysiology to intervention
Azemi, A. K., Mutalub, Y. B., Abdulwahab, M., Rasool, A. H. G., Mustapha, S., Suhaimi, S. Q. A., & Mokhtar, S. S. (2025) · Obesity Medicine · doi:10.1016/j.obmed.2025.100588 · Cited by 8
Cataldi, S., Aprile, M., Perfetto, C., Angot, B., Cormont, M., Ciccodicola, A., Tanti, J., & Costa, V. (2023) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2023.151320 · Cited by 4
Sridhar, A., Khan, D., Flatt, P. R., Moffett, R. C., & Irwin, N. (2023) · Peptides · doi:10.1016/j.peptides.2023.171093 · Cited by 6
A Gut-Centric Model of Metabolic Homeostasis
Rajagopalan, H., López-Talavera, J. C., Klonoff, D. C., & Cherrington, A. D. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211044523 · Cited by 5
Phan, C., & Wagner, E. J. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.11.038 · Cited by 4
Wu, B., Falsey, J. R., Netirojjanakul, C., Herberich, B., Holder, J. R., Sham, K. K. C., Aral, J., Forsythe, N., Walker, K. W., Lu, S.-C., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00032 · Cited by 4
Self-citationMetformin Boosts Intestinal Lipid Sensing via GIP to Suppress Feeding
Kuah, R., Wang, M. T., Yang, Z., Back, G., Li, R., Bruce, K., LoChoy, J. N., Beaudry, J. L., Barros, D. R., Zhang, S., et al. (2025) · Diabetes · doi:10.2337/db25-0100 · Cited by 5
Molecular basis of signal transduction mediated by the human GIPR splice variants
Zhao, F., Hang, K., Zhou, Q., Shao, L., Li, H., Li, W., Lin, S., Dai, A., Cai, X., Liu, Y., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2306145120 · Cited by 4
“Bidirectional regulation of carbohydrate levels by GIP is essential to the maintenance of glucose homeostasis, although this hinders the development of therapeutic agents targeting GIPR (55).”
West, J. A., Ghosh, S. S., Parkes, D. G., Tsakmaki, A., Grønlund, R. V., Pedersen, P. J., MAGGS, D. G., Rajagopalan, H., & Bewick, G. A. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/822122 · Cited by 3
Portha, B., Liu, J., Movassat, J., & Tourrel‐Cuzin, C. (2024) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2024.09.003 · Cited by 3
Szostak, B., Kułaga, M., Kasprzak, A., Grzybek, M., Mazur-Lesińska, D., Wielgosz-Biała, S., Tyszkiewicz, K., Łozowski, B., Kasprzak, M., & Wilczyńska, B. (2025) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.361 · Cited by 3
Revitalizing GIP: Therapeutic Potential in Metabolic and Neurodegenerative Disorders
Qiao, Y., Zhou, F., Mao, T., & Gao, L. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s559587 · Cited by 4
“18 Besides, infusion of the GIP receptor antagonist GIP 3–30NH2 can inhibit about 80% of GIP’s insulinotropic effect in T2DM patients.”
GIPR signaling modulates PYY-induced hypophagia and malaise in rodents
Borner, T., Pataro, A. M., Curtis, G. R., Alonso, B., Hu, J., Fortin, S. M., Koul‐Tiwari, R., Hughes, E. A. G., Kong, J., Jordan, E., et al. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102334 · Cited by 2
“Remarkably, several pre-clinical studies and clinical trials demonstrated that combining GIPR and GLP-1R agonism led to greater body weight loss and superior glycemic control compared to GLP-1R agonism alone [20 — 24].”
GIP receptor agonism suppresses inflammation-induced aversion and food intake via distinct circuits
Province, H. S., Hayes, N. W., Leong, N. A., Tang, E., Lorch, C. M., Pekerman, A., Xia, J. L., & Beutler, L. R. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117116 · Cited by 3
The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms
Davies, I., Holst, J. J., ROSENKILDE, M. M., & Tan, T. (2026) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-061824-043740 · Cited by 3
Damhof, M. A., van Bruggen, F. H., & Roon, E. N. V. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71075 · Cited by 3
Mitigating Diabetic Foot Ulcers: The Effect of Diet and Microbiome
Coon, S. D. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.106629 · Cited by 2
Gut-derived peptide hormone receptor expression in the developing mouse hypothalamus
Cantacorps, L., Coull, B. M., Falck, J. E., Ritter, K., & Lippert, R. N. (2023) · PLoS ONE · doi:10.1371/journal.pone.0290043 · Cited by 4
“Many novel therapeutics with extreme success in treating metabolic diseases are analogues of gut-derived peptide hormones, such as semaglutide, a glucagonlike peptide 1 (GLP1) receptor (GLP1R) agonist [3, 4].”
BackgroundPortha, B., Liu, J., Movassat, J., & Tourrel‐Cuzin, C. (2025) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2025.05.006 · Cited by 1
Metadata
- Authors
- Killion, E. A., Wang, J., Yie, J., Shi, S. D.-H., Bates, D., Min, X., Komorowski, R., Hager, T., Deng, L., Atangan, L., Lu, S.-C., Kurzeja, R. J. M., Sivits, G., Lin, J., Chen, Q., Wang, Z., Thibault, S. A., Abbott, C. M., Meng, T., Clavette, B., Murawsky, C. M., Foltz, I. N., Rottman, J. B., Hale, C., Véniant, M. M., & Lloyd, D. J.
- Affiliations
- Amgen (United States) (US)
- Amgen Research, Department of Cardiometabolic Disorders, Amgen Inc., One Amgen Center Dr., Thousand Oaks, CA 91320, USA.
- Amgen Research, Department of Therapeutic Discovery, Amgen Inc., One Amgen Center Dr., Thousand Oaks, CA 91320, USA.
- Amgen Research, Department of Therapeutic Discovery, Amgen Inc., 7990 Enterprise Street, Burnaby, BC V5A 1V7, Canada.
- Corresponding author
- Killion, Elizabeth A.
- Wang, Jinghong
- Yie, Junming
- Lloyd, David J.
- ORCID
- Killion, Elizabeth A.
- Wang, Jinghong
- Yie, Junming
- Shi, Stone D.-H.
- Bates, Darren
- Min, Xiaoshan
- Komorowski, Renee
- Deng, Liying
- Lu, Shu-Chen
- Kurzeja, Robert J. M.
- Sivits, Glenn
- Chen, Qing
- Wang, Zhulun
- Thibault, Stephen A.
- Abbott, Christina M.
- Clavette, Brandon
- Murawsky, Christopher M.
- Rottman, James B.
- Hale, Clarence
- Véniant, Murielle M.
- Lloyd, David J.
- Venue
- Science Translational Medicine
- Published
- 2018-12-19
- Volume
- 10
- Issue
- 472
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2904833368
- Cited by
- 237
- References
- 42
- Citations by year
- 2026: 32 · 2025: 33 · 2024: 33 · 2023: 28 · 2022: 31 · 2021: 31 · 2020: 20 · 2019: 27
- FWCI
- 11.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen Inc
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- GIP receptor antagonist, obesity, diet-induced obesity, GLP-1 receptor agonists, combination therapy, weight loss, dietary intake, respiratory exchange ratio, non-human primates, pancreatic beta cells, obesity treatment
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Antibodies, Diet, Drug Therapy, Combination, Glucagon-Like Peptides, Feeding Behavior, Gastric Inhibitory Polypeptide, Humans, Immunoglobulin Fc Fragments, Mice, Obese, Obesity, Primates, Receptors, Gastrointestinal Hormone, Recombinant Fusion Proteins, Respiration, Weight Gain, Weight Loss, Adipocytes, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.